Overview
- Meant Health expanded its telehealth platform to provide access to FDA-approved GLP-1 medications following evaluation by US-licensed clinicians.
- Patients complete an intake covering their health history, current medications, and treatment goals before a clinician determines eligibility.
- Qualified patients receive ongoing care coaching and follow-up support alongside their prescribed treatment.
The News
Meant Health is expanding its digital health platform to connect patients with licensed clinicians for evaluation, prescription, and ongoing care related to GLP-1 medications. The process begins with an online health questionnaire, followed by a case-by-case review by a U.S.-licensed clinician.
Patients who qualify may receive FDA-approved GLP-1 medications, including Ozempic, along with personalized care coaching and follow-up. While Ozempic is FDA-approved for type 2 diabetes, its use for weight management is off-label and remains at the clinician’s discretion.
Industry Perspective
Telehealth platforms are increasingly providing more convenient access to clinician-led evaluation and treatment for obesity and metabolic health. Combining virtual clinical assessment with ongoing coaching can help address the need for continued support beyond a one-time prescription.
Strategic Impact
The expansion strengthens Meant Health’s position in the growing digital GLP-1 care market by combining medication access with clinician oversight and ongoing coaching. This integrated model could help differentiate the platform from services focused primarily on prescription access.
Source: PRnewswire
